Overview
RNTX market data
Price History
RNTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.96 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.36 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.73 – $2.18 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $65.2 · P/B 1.80.
Company News
Rein Therapeutics Begins Enrolling Patients In Phase 2 RENEW TrialBenzinga · Jul 21, 2026, 12:05 PM
Maxim Group Initiates Coverage On Rein Therapeutics with Buy Rating, Announces Price Target of $4Benzinga · Jul 20, 2026, 6:13 PM
HC Wainwright & Co. Maintains Buy on Rein Therapeutics, Lowers Price Target to $8Benzinga · Jun 1, 2026, 10:42 AM
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment OptionBenzinga · May 18, 2026, 12:15 PM
Rein Therapeutics Q1 EPS $(0.19) Beats $(0.49) EstimateBenzinga · May 15, 2026, 1:35 PM
8-K filing — Rein Therapeutics, Inc. (RNTX)SEC EDGAR · May 4, 2026, 8:12 PM